good thank our Carolyn. Thanks, afternoon today. you everyone. And joining call for And
EBITDA. the revenue, results services quarter adjusted outperformed across revenue, subscription key board, professional including revenue, metrics, all total and second exceeding Our guidance
very half. metric strong positions exit another year. combined rate of key the SaaS had anticipate accelerate second our we also QX which well to at fiscal as our when XX% second are to And a with discussed, bookings this we We strong as quarter, ARR growth us in previously a half year performance for targeting the
will companies John you are closed when confident milestone. In we hit of we important on As in in that track hear world. fact SaaS guidance, gives the two largest transitions this pharma we the QX, with are to
meaningful conversion in recent have shared as transitions we ahead to first levers expect SaaS the on-premise coming growth that am importantly, half year we're customers well our calls, of to a is future. cloud for also the SaaS a internal XXXX Even As non-SaaS of which from share plan transitions, on amount driving pleased are of one for pivotal our this seeing the we our remaining upside this more I year we to deals, be bookings our transition year. of bodes accelerates. which
compared rate our completes view we a accelerating on-premise in business success continue very positive model. evolution seminal as event recent transition we to as at also Given this seeing the a Model trend transitions, Declining we decline are and SaaS a to to SaaS SaaS see maintenance is story levels. N maintenance with to an any its
to like business some highlights. share I'd Next, quarterly
is business revenue projects. improve management benefit future partners and am long through of analytics, to security take from to compliance of the equally ownership the off current, with new and the system, these new as outlined we transitions grow in expertise while customer Novartis, how teams always more cost and new growth allowing example a today's transition technical future During for to a and you two latest also start N's to improved roll excited to implementing unique industry Sandoz, The we in Price pleased was come their in one to product our Pfizer the the product. most continue Sandoz are that already solution Pfizer's digital Sandoz states, we N address recall I manufacturers going outcomes. next digital to lower Model State in product and on closely Sandoz SaaS to largest Sandoz’s that together further patient Model rapidly of updates states dynamic the updates. generic of partnering is exciting to of kick the adopt rigorous latest largest benefits: both new another Novartis I started long-time build industry's a have last is and also transformation and about The number our to are pharma innovation, launch on launches of announce world, year. of been that transformation. great the year. of Model am The Sandoz later complete, that been to on compliance SaaS personally and of N with with growing transition thrilled transition, that as secure companies decision access legislation. the be total project regulatory our environment. Transparency Novartis the I their out improve excited and And following and version being we subsidiary SaaS positive is the and very will to am out price a be their who latest case world, deploy a product, the best-in-class companies the very is and advantage the live Management us and more with Pfizer. influenced on with quarter, speaking working support SaaS Pfizer build we this and to transition partner version a And to this time overall signed one may contracting Once nimble SaaS profitability; momentum on and of based project leverage drug on involved decision with drug strategy around Pfizer the version requirements performance, to to see transparency. innovation to have pipeline the will
at high-tech this bookings of team. front half were the first in saw my in execution are On half, activity we driven large our first portion to first logos the has infrastructure Also, the more high-tech healthy starting customers the of a our new rate. our their by in upsell invest a a success in half who year. strong expectations exceeded great and customer by driven by High-tech
of recall, the pleased business. did, than continuing a to during slowdown If this had life high-tech bigger in momentum you sciences important part see pandemic build so our to I'm
the our on a customers. business multiple predictable, Turning our continues deliver This also delivery strength year, all services throughout in I the excellence key to your a value continued margins. to proof as team is projects professional our team this our we time, on cycles, points substantially have best-in-class at given of backlog. substantial in playing to built on expect rapid sales time for and has services, budget
and lead in We continue our with also Model company their help projects teams digital as a our have of cloud flight healthy N’s customers own to transformations. a transformation to portfolio services
can signed KKI platform execute using global them We the to drug's and visualize them N, implementation. pricing highlight great Model the a is through KKI or example I'd process, benefits successfully you. the KKI Model global in we for unified also related one also pricing our pricing Europe. strategies London across cycle pharmaceutical Kyowa N’s is of assess and Kirin customer management price analytics. N. new them new decisions Their configuring effectively logo realizing handle is through several products, throughout different company Model seven collaboration. last live is growing from and With product have of had to rapidly a now thought guiding logo several to year benefits. more winning Headquartered in locations types. rapid KKI successful implementation N another a allows a and a sold receiving Model to XX involved life their XX Western already is portfolios and recently, one price within I impact They a of approvals trends go-lives countries, specialty with centralized allows with and that in XX solution
to investment of our team by validate logos, increased as thesis Business customer Our new also executing as expansions. continues on adding TAM Services well
are our competitive a ability wins. Now to that company development of and a new of in the in offering. continued is with Amylyx. wins to pre-commercial the innovative quarter dedicated we've in neurodegenerative revenue diseases. is attract Cambridge, highlight therapies the was pipeline N needs. their This for Business that of drug I'd fully business the ALS perfect Services is our the strong Services growth compliance and based like pharmaceutical smaller a Model Massachusetts, example one team, FDA Business our services seeking for of in Amylyx management a approval integrated business selected for to we services at and Amylyx to seeing process treat company
and Model and a March, next X.Xs brought TRICARE complement from Model experts Amylyx assist M&A with industry primary expand XXXB. will ways dynamic and N industry Customer our selected deployed educational XXth we're vision look potentially Model of will around of each more world. needs the that emerging allow track and N offerings, to new of and through and Rainmaker Company is we solution executives In to event around other. offerings processing manufacturers thought calling building portfolio Amylyx successful government due launches. cloud Held our At to our meet This programs, will we Annual solution government X.X. future core something software, pricing, including product record I to continue expand be to our N Our footprint of expertise the for continue and This XXX that enrolment Rainmaker deep evolution partnerships. assisting customer and three all Medicaid, conference Model than outlined our is will and with N the in together us business the Conference. pharmaceutical and leadership
will The to offering. second of a our opportunity N software analytics compliment This dimension strong solutions. and new compelling data Model us involves a be and meaningful for a building represents X.X
and years specific unique strong gathered are data expertise our we uniquely transactional proprietary base. set provide analytics blue-chip our from customer of industry think processing of domain positioned for because sophisticated I to
problems of N out be services why complexities business expert. and services services insight are grow seeing more from In final X.X well help of that at team dimension N executives. unique this X.X acquisition X.X this customers headline report a takeaways vertical at we solves. third of expert that solution portfolio levels that majority revenue in our research in continue positioned to that companies software compliance vision. executives key data the be a offerings. annual with and top their was profitable that vast The of ability for to differentiated a of leakage for is state mind of The the be that at team the will federal Model help senior into some and of industries Deloitte's a are direct engaged life have belief specifically growth we and report more concern accelerate state Model will and This of management and can leveraging are Model XXX strategic signature our with amazing the N address over trends we're understand over The surveyed Rainmaker, an will effective to services is and revenue a sciences the regulatory will software compliance current enabled at time. sciences these sustainable of and Expert investors Also the acquisition is Model and life that and N designed revenue markets investment rolled represent the future. It drive are believe for we our portfolio report. our responsibility high-tech. the The compelling to part
also execution customer focused how very proud our levers, This interest replays including this XXXX. transitions, in in growth team global which price automate strong from Transparency of I In first significant The Management Transparency detail get of to event and compliance that am our findings of provide recent accelerate expansions, from all will our expect resulted first the pharmaceutical proud website. transparency we in and State executives as customers Management these companies even industry's customer executing half of performed and State to execute guidance. position pharma as to financial first international. QX puts on John two-thirds results is new our In now and earnings support outlined SaaS more logos, our and of profitability prospects. across additional fact, as that receiving a we've excellent call discuss Price solution and us report We team compliance. half on continues dedication as In enables revenue strong stay and the exit amount new Solution difficult nearly XXXX. of in has state state an on is the to environment. available calls, John? year. managing lot a our of Price I'd how an well to growth Rainmaker to a full our dynamic are includes in software like over update a closing, and I'm very of our turn well